ArticleBMC nutrition2025
Evaluation of Streptococcus faecalis, Clostridium butyricum, Bacillus mesentericus, Lactobacillus sporogenes, Saccharomyces Boulardi multistrain probiotic formulation in acute gastroenteritis: a real-world observational study (MAESTRO).
Article in BMC nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiome remodeling induced by microplastic exposure in humans.Gut microbes · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastroenteritis is a leading cause of global morbidity, characterized by inflammation of the stomach, small intestine, or large intestine, resulting in diarrhea, vomiting, and abdominal pain. Acute gastroenteritis (AGE) typically resolves within 14 days, but probiotics are increasingly used to restore gut microbiota balance and counteract pathogenic organisms. This study evaluates the safety and efficacy of a novel multistrain probiotic formulation in managing AGE and antibiotic-associated diarrhea (AAD).
methodsThis observational, real-world study included 683 patients from 239 sites across India, assessing the effects of a multistrain probiotic formulation in AGE and AAD. The study adhered to ICH-GCP guidelines and the Declaration of Helsinki, with Ethics Committee approval. Clinical outcomes were assessed based on stool frequency, consistency, and Clinician's Global Impression of Improvement (CGI-I) scores after 7 days of treatment. Statistical analyses were conducted using SPSS version 29.0.1.0 to evaluate significant changes in these parameters.
resultsAmong AGE patients (mean age: 45.91 ± 11.77 years; 68.92% male), 56.42% had no comorbidities. The most common symptoms were diarrhea (96.70%) and abdominal cramps (37.67%). Probiotics were prescribed to 93.92% of patients, with 93.23% achieving diarrhea resolution. Stool frequency significantly declined from 5.63 ± 1.43 to 1.65 ± 0.65 per day (68.94% reduction, p < 0.0001), and 95.31% of patients achieved normal stool consistency. CGI-I scores improved in 99.83% of cases. Among AAD patients (mean age: 43.32 ± 11.64 years; 60.75% male), diarrhea (97.20%) and vomiting (30.84%) were predominant symptoms. Probiotics were prescribed to 99.07% of patients, with an equal proportion achieving diarrhea resolution. Stool frequency significantly decreased by 67.94% (p < 0.0001), and Oral Rehydration Solution (ORS) use declined from 54.21% at baseline to zero by Day 7. No treatment-related adverse events were reported.
conclusionThe multistrain probiotic formulation significantly improved stool frequency and consistency in AGE and AAD patients within 7 days. Additionally, it effectively reduced ORS dependence and exhibited a strong safety profile, with no reported adverse events. These findings support the probiotic's potential as a safe and effective adjunct in managing AGE and AAD.
trial registrationThis clinical study was registered at CTRI (Clinical Trial Registry of India) under the Registered number CTRI/2024/01/061546 on 17 Jan 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.